Key result
Ticagrelor-based DAPT fails to prevent subacute stent thrombosis and coronary aneurysms linked to COVID-19.
Why the study?
COVID-19 can have important cardiovascular implications, including arterial and venous thrombosis, but specific rare complications require clinical description.
Case Report (n=1)
Highlights a rare case of subacute stent thrombosis and coronary artery aneurysms in a COVID-19 patient despite adherence to potent dual antiplatelet therapy.
Answers are grounded in this paper and cite their sources.
Suggests possible COVID-19 link to stent thrombosis and aneurysms despite ticagrelor; hypothesis-generating and should not change practice.
Coronavirus disease 2019 (COVID-19), although predominantly a respiratory illness, can have important cardiovascular implications, which include the development of myocardial injury/myocarditis, acute coronary syndromes, arrhythmias, pericarditis, and the occurrence of arterial and venous thrombosis. We describe a rare case of a middle-aged COVID-19 patient who developed sub-acute stent thrombosis after implantation of second-generation drug-eluting stents (DES) despite being adherent to dual antiplatelet therapy including ticagrelor and who subsequently developed multiple coronary artery aneurysms within a few weeks of the DES implantation.
No takes yet. Share an insight, caveat, or question.
Sidhu et al. (2022) conducted a case report in COVID-19, Subacute Stent Thrombosis, Coronary Artery Aneurysms (n=1). COVID-19 infection after PCI with drug-eluting stents was evaluated. A 56-year-old male developed subacute stent thrombosis despite adherence to ticagrelor-based dual antiplatelet therapy, followed by multiple coronary artery aneurysms, likely due to COVID-19.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: